PATENTS

MAIL CERTIFICATION

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner of Patents,

Washington, D.C. 20231 on March 2, 2000

Bruce S. Londa

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

GROUP ART UNIT : 1643

APPLICANT

: Timo Hillebran

APPLN. NUMBER

: 09/454,740

FILED

: December 6, 1999

FOR

: Formulations and Method for Isolating Nucleic Acids from Optional Complex Starting Material and Subsuquent Complex Gene Analytics

tty's Docket No.: 2936.166/00

REQUEST FOR CORRECTION OF FILING RECEIPT

Hon. Assistant Commissioner of Patents Box Missing Parts Washington, D.C. 20231

Sir:

We are returning herewith the filing receipt prepared for the above-identified patent application. We would like to respectfully point out that the title is incorrect on this filing receipt, namely "sebsequent" should be --subsequent-- as noted on the enclosed receipt.

Please issue a corrected filing receipt.

Respectfully Submitted,

Bruce S. Londa (33,531) Attorney for Applicant Londa and Traub LLP

20 Exchange Place, 37th Floor

New York, N.Y.10005 Telephone: (212)968-1300

Telefax: (212)968-1307

FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE Patent, and Trademark Office ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT FIL FEE REC'D ATTORNEY DOCKET NO. DRWGS TOT CL	IND CL
09/454,740	Harris Harris Harris	그리트를 잃다 마양화를 위하는 것을 못하는 경험 환경한 사람들은 경험 환경 등 사람들이 되었다.	1

BRUCE S LONDA LONDA AND TRAUB LLP 20 EXCHANGE PLACE 37TH FLOOR NEW YORK NY 10005

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an arror is noted on this Filing Receipt, please write to the Office of initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts of Application" ("Missing Parts Notice") in this application, please submit any corrections to this Filing Receipt with your reply to the "Missing Parts Notice." When the PTO processes the reply to the "Missing Parts Notice." the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

TIMO HILLEBRAND, BERLIN, FED REP GERMANY; PETER BENDZKO, BERLIN, FED REP GERMANY.

FOREIGN APPLICATIONS-

FED REP GERMANY

198 56 064.8

12/04/98

IF REQUIRED, FOREIGN FILING LICENSE GRANTED 01/07/00 ** SMALL ENTITY **

FORMULATIONS AND METHOD FOR ISOLATING NUCLEIC ACIDS FROM OPTIONAL COMPLEX STARTING MATERIAL AND SPRSEQUENT COMPLEX GENE ANALYTICS

PRELIMINARY CLASS: 530

DATA ENTRY BY: KING, DORIS

TEAM: 04 DATE: 01/07/00

L. INSE FOR FOREIGN FILING UNE Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "FOREIGN FILING LICENSE GRANTED" followed by a date appears on the reverse side of this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.11. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date; thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR Parts 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time; if the phrase "EORLIGN FILING LICENSE GRANTED" DOES NOT appear on the reverse side of this form. Applicant may still petition for a license under 37 CFR 5.12; if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

PLEASE NOTE ---- The Following Information: about the Filing Receipt:

The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.

The words "new," "improved," "improvement;" "improvements in or relating to" are not included as the first words in the title of an application because a patent application is, by nature, a new idea or improvement.

The title may be truncated if it consists of more than 4 lines of 70 characters each detters and spaces combined).

The inventor information may be truncated if the family name consists of more than 25 characters (letters and spaces combined) and if the given name consists of more than 25 characters (letters and spaces combined). The inventor's residence allows for up to 40 characters (letters and spaces combined).

The docket number allows a maximum of 12 characters.

If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in"

Customer Address may have been modified to conform to U.S. Postal rules 1.2.

Please direct correction, including a copy of your Filing Receipt; to:

Assistant Commissioner for Patents
Office of Initial Patent Examination
Customer Service Center
Washington, DC 20231